Activation of PPAR-α in the early stage of heart failure maintained myocardial function and energetics in pressure-overload heart failure

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 312, Issue 2, 2017, Pages H305-H313

  Kaimoto, Satoshi ^a   Hoshino, Atsushi ^a   Ariyoshi, Makoto ^a   Okawa, Yoshifumi ^a   Tateishi, Shuhei ^a   Ono, Kazunori ^a   Uchihashi, Motoki ^a   Fukai, Kuniyoshi ^a   Iwai Kanai, Eri ^a,b   Matoba, Satoaki ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b TENRI HEALTH CARE UNIVERSITY   (Japan)

Author keywords

Energy metabolism; Fatty acid oxidation; Heart failure; PPAR

Indexed keywords

CARNITINE PALMITOYLTRANSFERASE I; CREATINE PHOSPHATE; DOXYCYCLINE; DRINKING WATER; FATTY ACID TRANSPORT PROTEIN 1; FATTY ACID TRANSPORTER; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHOSPHATE; PIRINIXIC ACID; UNCLASSIFIED DRUG; FATTY ACID; GLUCOSE; PYRIMIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; BODY WEIGHT; COMPARATIVE STUDY; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENERGY TRANSFER; EX VIVO STUDY; FATTY ACID METABOLISM; GLUCOSE OXIDATION; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; HIGH ENERGY PHOSPHATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; ISOLATED HEART; MALE; METABOLIC RATE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRESSURE OVERLOAD HEART FAILURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SYSTOLIC BLOOD PRESSURE; SYSTOLIC DYSFUNCTION; WESTERN BLOTTING; AGONISTS; ANIMAL; AORTA; CARDIAC MUSCLE; DISEASE MODEL; DRUG EFFECTS; ENERGY METABOLISM; GENETICS; HEART CONTRACTION; METABOLISM; OXIDATION REDUCTION REACTION; PATHOPHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURGERY; TRANSGENIC MOUSE;

ANIMALS; AORTA; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; ENERGY METABOLISM; FATTY ACIDS; GLUCOSE; HEART FAILURE; MALE; MICE; MICE, TRANSGENIC; MYOCARDIAL CONTRACTION; MYOCARDIUM; OXIDATION-REDUCTION; PHOSPHATES; PPAR ALPHA; PYRIMIDINES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VENTRICULAR DYSFUNCTION, LEFT;

EID: 85013469521     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00553.2016     Document Type: Article

References (24)

1. ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR III, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC Jr, Cushman WC, Simons-Morton DG, Byington RP. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362: 1563-1574, 2010. doi:10.1056/NEJMoa1001282.
2. Allard MF, Schönekess BO, Henning SL, English DR, Lopaschuk GD. Contribution of oxidative metabolism and glycolysis to ATP production in hypertrophied hearts. Am J Physiol Heart Circ Physiol 267: H742-H750, 1994.
3. Aoyama T, Peters JM, Iritani N, Nakajima T, Furihata K, Hashimoto T, Gonzalez FJ. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor α (PPARalpha). J Biol Chem 273: 5678-5684, 1998. doi:10.1074/jbc.273.10.5678.
4. Australia-New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 349: 375-380, 1997.
5. Barger PM, Brandt JM, Leone TC, Weinheimer CJ, Kelly DP. Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth. J Clin Invest 105: 1723-1730, 2000. doi:10.1172/JCI9056.
6. Bing RJ. The metabolism of the heart. Harvey Lect 50: 27-70, 1954-1955.
7. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N; MOCHA Investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 94: 2807-2816, 1996. doi:10.1161/01.CIR.94.11.2807.
8. Brown JD, Plutzky J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation 115: 518-533, 2007. doi:10.1161/CIRCULATIONAHA.104.475673.
9. Duhaney TA, Cui L, Rude MK, Lebrasseur NK, Ngoy S, De Silva DS, Siwik DA, Liao R, Sam F. Peroxisome proliferator-activated receptor alpha-independent actions of fenofibrate exacerbates left ventricular dilation and fibrosis in chronic pressure overload. Hypertension 49: 1084-1094, 2007. doi:10.1161/HYPERTENSIONAHA.107.086926.
10. Ericsson CG, de Faire U, Grip L, Svane B, Hamsten A, Nilsson J. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 347: 849-853, 1996. doi:10.1016/S0140-6736(96)91343-4.
11. Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, Han X, Gross RW, Kozak R, Lopaschuk GD, Kelly DP. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest 109: 121-130, 2002. doi:10.1172/JCI0214080.
12. Huss JM, Kelly DP. Nuclear receptor signaling and cardiac energetics. Circ Res 95: 568-578, 2004. doi:10.1161/01.RES.0000141774.29937.e3.
13. Ingwall JS. Energy metabolism in heart failure and remodelling. Cardiovasc Res 81: 412-419, 2009. doi:10.1093/cvr/cvn301.
14. Jia Z, Xue R, Liu G, Li L, Yang J, Pi G, Ma S, Kan Q. HMGB1 is involved in the protective effect of the PPARα agonist fenofibrate against cardiac hypertrophy. PPAR Res 2014: 541394, 2014. doi:10.1155/2014/541394.
15. Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, Grobbee DE, Cass A, Chalmers J, Perkovic V. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 375: 1875-1884, 2010. doi:10.1016/S0140-6736(10)60656-3.
16. Lionetti V, Stanley WC, Recchia FA. Modulating fatty acid oxidation in heart failure. Cardiovasc Res 90: 202-209, 2011. doi:10.1093/cvr/cvr038.
17. Lopaschuk GD, Belke DD, Gamble J, Toshiyuki I, Schönekess BO. Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochim Biophys Acta 1213: 263-276, 1994. doi:10.1016/0005-2760(94)00082-4.
18. Neubauer S. The failing heart--an engine out of fuel. N Engl J Med 356: 1140-1151, 2007. doi:10.1056/NEJMra063052.
19. Smeets PJ, Teunissen BE, Willemsen PH, van Nieuwenhoven FA, Brouns AE, Janssen BJ, Cleutjens JP, Staels B, van der Vusse GJ, van Bilsen M. Cardiac hypertrophy is enhanced in PPARα-/-mice in response to chronic pressure overload. Cardiovasc Res 78: 79-89, 2008. doi:10.1093/cvr/cvn001.
20. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 85: 1093-1129, 2005. doi:10.1152/physrev.00006.2004.
21. Wallhaus TR, Taylor M, DeGrado TR, Russell DC, Stanko P, Nickles RJ, Stone CK. Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. Circulation 103: 2441-2446, 2001. doi:10.1161/01.CIR.103.20.2441.
22. Watanabe K, Fujii H, Takahashi T, Kodama M, Aizawa Y, Ohta Y, Ono T, Hasegawa G, Naito M, Nakajima T, Kamijo Y, Gonzalez FJ, Aoyama T. Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor alpha associated with age-dependent cardiac toxicity. J Biol Chem 275: 22293-22299, 2000. doi:10.1074/jbc.M000248200.
23. Yang Q, Li Y. Roles of PPARs on regulating myocardial energy and lipid homeostasis. J Mol Med (Berl) 85: 697-706, 2007. doi:10.1007/s00109-007-0170-9.
24. Young ME, Laws FA, Goodwin GW, Taegtmeyer H. Reactivation of peroxisome proliferator-activated receptor alpha is associated with contractile dysfunction in hypertrophied rat heart. J Biol Chem 276: 44390-44395, 2001. doi:10.1074/jbc.M103826200.